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Abstract
Background: Human Papillomavirus (HPV) is a well-known pathogen for lower genital tract
neoplasias, yet little is known regarding HPV prevalence in Turkey. The aim of this study was to
investigate the prevalence of HPV DNA and to determine HPV types distribution among women
with normal and abnormal cytology.
Methods: A total of five hundred seven (n = 507) women were retrospectively evaluated between
2004-2008. Conventional polymerase chain reaction was used to detect the presence of HPV types
in cervicovaginal samples obtained from patients during gynecologic examination.
Results: One hundred four (n = 104) of the women were excluded from the study because of the
incomplete data and a total of 403 women were used for the final analysis. There were, 93 (23%)
women with cytologic abnormality and 310 (77%) women with normal cytology. Overall, 23% of
the women was HPV positive. The overall prevalence of HPV in women with abnormal Pap smears
was 36% (93/403), of which in ASCUS 22%, LSIL 51% and HSIL 60%. Also, HPV DNA was positive
in 20% of the women with normal cervical cytology. The most common HPV types in cytologically
normal women were as follows; HPV 16 (36%), HPV 6 (22%) and HPV 18 (13%). The rate of other
HPV types were as follows; HPV11 4.4%, HPV45 4.4%, HPV90 4.4%, HPV35 2.2%, HPV67 2.2%,
HPV81 2.2%, and multiple type HPVs 8.9%. The most common HPV types in cytologically abnormal
women were HPV 16 (35%), HPV6 (19%) and HPV18 (8%). The rate of multiple HPV infections in
women with normal Pap test was 2.2%.
Conclusion: HPV prevalence and type distribution in this study were similar to that reported
worldwide at least in our study population. Hovewer, HPV prevalence was more common
compared with previous studies reported from Turkey. This might be related with methodology
and hospital based patient accrual and high rate of women with abnormal cytology. Further
population based prospective studies are needed to eliminate the drawbacks of our study and to
determine nonhospital based HPV prevalence in Turkish women.
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Background
Cervical cancer is the one of the leading cause of cancer-
related deaths among women worldwide. It is e estimated
500,000 cases occurring annually and a 50% case fatality
rate [1].
According to statistics of Ministry of Health and GLOBO-
CAN 2002, cervical cancer is the 9th most common cancer
among women in Turkey and ranks 13th among cancer-
related deaths, with an estimated 1364 cases occurring
annually and more than 50% of fatality rate [2].
Today, it is widely accepted that Human papillomavirus
virus (HPV) is the main causal factor of cervical carci-
noma. More than 100 HPV genotypes have been
described and nearly 20 of them have been associated
with cervical carcinoma. It has been reported that HPV
prevalence range between 1.4% to 25.6% in the world [3].
Previous studies reported that HPV prevalence between
2% to 6% among the low risk women in Turkey [4-8].
However, these studies generally included small number
of cases or performed by using Hybrid Capture I or II. The
aim of this study is to investigate the HPV prevalence by
using PCR method and to report the rate of HPV infection
in women with normal and abnormal cervical cytology.
Methods
Between January 2004 and August 2008, 503 consecutive
sample of women attending gynecological outpatient
clinics for regular gynecologic control in Baskent univer-
sity School of Medicine, Departments of Obstetrics and
Gynecology were included to this retrospective analysis.
Women were eligible if they had no previous diagnosis or
treatment for cervical, vulvar or vaginal cancer and ever
sexually active. Also, patients with previous history of
chemoradiotherapy for cervical carcinoma were excluded
from the analysis. Information on sociodemographic
characteristics, medical history and sexual and reproduc-
tive behaviour was obtained at the time of the gynecolog-
ical visit which was filled during the gynecological visit.
Samples of exfoliated cervical cells were obtained using a
cytobrush. After the preparation of a standard cervical
smear, the remaining cells were placed in tubes with 0.9%
saline and stored at - 201C until shipment to the our
microbiology laboratory. Pap smears were classified
according to the Bethesda system by pathology depart-
ment. HPV DNA detection and genotyping performed by
PCR in our microbiology labaratory as described previ-
ously [9]. The data were analysed by of the t test, continu-
ity-corrected chi-square method or Fisher's exact test, One
way Anova, calculation of prevalence ratio and descriptive
statistics as required, and the probability type I error was
set at 0.05 (two-tailed). Prevalence ratio for each decads
(2th, 4th and 5th) calculated by comparing with 3rd
decad using poisson regression with robust variance esti-
mates as described previously [10,11] Statistical analysis
performed by SPSS v.11.5.
HPV DNA detection and genotyping
HPV DNA detection in cervical swabs was conducted by
using real-time polymerase chain reaction (PCR) with a
commercial kit (Fluorion, Iontek, Turkey). For DNA
extraction the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) was used in accordance with the instructions of
the manufacturer. A 150 bp fragment of the L1 gene was
amplified using GP5 and GP6 primers. An amplified gene
product was identified via melting curve analysis and vis-
ualized by incorporation of Sybr Green dye during ampli-
fication. HPV genotyping was performed with DYEnamic
ET Terminator Cycle Sequencing Kit (Amersham Bio-
sciences Corp., NJ, USA) and ABI PRISM 310 Genetic Ana-
lyzer at Iontek Ltd, Turkey.
The study protocol was approved by at Ethical Board of
Baskent University, School of Medicine.
Results
During the four year period, 503 women who attend for
regular gynecological examination were analyzed for HPV
in our departments. One hundred four of these women
were excluded from the analysis because of the incom-
plete data and a total of 403 women were used for the
final analysis.
Mean age of the patients was 37.5 ± 9.3 (range 19-67 y).
Ninety percent of the population was premenaposal while
10% was menopausal. There were significant differences
with respect to HPV positivity between women under 30
years old and women older than 30 years old (34%
vs.20%, p = 0.005) but, there was no significant differ-
ences with respect to decads of life and HPV positivity.
Also, menopausal status has no effect on HPV positivity.
HPV was positive in 24% of the premenopausal women
and 17% of the menopausal women (p = 0.323).
There were, 93 (23%) women with cytologic abnormality
and 310 (77%) women with normal cytology. Cervical
cytologic abnormalities were diagnosed as follows; 42%
atypical squamous cell of undetermined significance
(ASCUS), 46% low-grade squamous intraepithelial lesion
(LSIL), and 11% high-grade SIL (HSIL). Overall, 23% of
the women was HPV positive. On the other hand, HPV
was positive in the 36% of the women with cytologic
abnormalities and this figure was 20% in women without
cytologic abnomality. HPV was positive in 22%, 51%,
60% of the ASCUS, LSIL and HSIL respectively (Table 1).
The most common HPV types in cytologically normal
women were as follows; HPV 16 (36%), HPV 6 (22%) and
HPV 18 (13%). The rate of other HPV types were as fol-
lows; HPV 11 4.4%, HPV 90 4.4%, HPV 45 4.4%, HPV 67BMC Infectious Diseases 2009, 9:191 http://www.biomedcentral.com/1471-2334/9/191
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2.2%, HPV 81 2.2%, HPV 35 2.2%, and mixed type HPVs
8.9%. The most common HPV types in cytologically
abnormal women were HPV 16 (35%), HPV 6 (19%) and
HPV 18 (8.8%) (Table 2). The prevalence ratio for 2nd,
4th, 5th and 6th decads of life comparing the 3rd decads
of life were 1.78, 1.12, 1.14 and 2.07, respectively (Table
3).
Discussion
Today, it is well known that some kind of cancers are
closely related with persistent infection of oncogenic types
HPV. On the basis of epidemiological and virological
studies, HPV is estimated to cause 100% of cases of cervi-
cal cancer, 90% of anal cancer, 40% of cancers of the exter-
nal genitalia (vulva, vagina and penis), at least 12% of
oropharyngeal cancers and 3% of oral cancers [12]. It has
been estimated that HPV is responsible for 5.2% of all
cancers worldwide [13]. Furthermore, Human papilloma-
virus (HPV) has been established as a necessary cause of
cervical cancer and its precursors, including cervical
intraepithelial neoplasias grades 2 and 3 (CIN 2-3). There-
fore, detection of high-risk HPV is becoming increasingly
attractive as a primary screening tool. Also, data for HPV-
type distribution is sine qua non to development of new
HPV-screening tests and to assessment of the effect of
future vaccination on HPV infections of differing severity,
but published data about the HPV prevalence in Turkey
limited [3-8].
Although Turkey has historically had low incidence rates
of invasive cervical cancer, cervical cancer ranks among
the 9th most common female malignancies with an age-
standardized incidence rate of 4.5 per 100.000. Our coun-
try has a more than 70 million population, but, unfortu-
nately, there is no population based studies which
investigating HPV prevalence in Turkish women. Previous
studies reported that HPV prevalence between 2%-6%
among the low risk women in Turkey (Table 4). In con-
trast, HPV prevalence and type distribution in our study
was similar to that reported worldwide. Our HPV preva-
lence is the highest rate reported from our country so far
and probably just reflect the HPV profile of our patients
population. We believe this high prevalence may arise
from the high rate of women with abnormal cervical
cytology, the higher educational status of our patient pop-
ulation [14,15]. hospital based patient accrual and usage
of more sensitive HPV evaluation method. As it can be
seen in Table 4, prevalence of HPV in Turkey was found 2
times higher in PCR studies compared with hybrid cap-
ture studies. Interestingly, Bao et al. reported that HPV
Table 1: Distribution of cervical cytology and HPV in the study population
Cytology Mean Age No. of Specimens
N,(%)
Overall HPV (+)
%
Normal 38.1 ± 9.4 (20-67) 310 (77%) 20%
Abnormal Cytology 35.6 ± 8.7
(19-58)
93 (23%) 36%
ASCUS 37.0 ± 8.8 39 (42%) 22%
LSIL 33.6 ± 8.9 43 (46%) 51%
HSIL 38.0 ± 6.9 10 (11%) 60%
Table 2: HPV type distribution in cases with normal and abnormal cytology
HPV Types in All Positive Patients (n = 93) Normal Cytology
(n = 310)
Abnormal Cytology *
(n = 93)
HPV 16 34% 37% 30%
HPV 6 17% 22% 13%
HPV 18 9% 14% 5%
HPV 35 8% 2% 17%
HPV 16+18
(Double HPV)
8% 7% 5%
HPV 11 4% 4% 5%
HPV 45 4% 4% 5%
HPV 31,33,45,52,58
(Multiple HPV)
4% 2% 8%
HPV 31 4% - 8%
HPV 90 3% 4% -
HPV 67 3% 2% -
HPV 81 2% 2% 4%
* HPV type distribution in all HSILs: HPV 16 in 50%, HPV18 in 25% and HPV 6 in 25%BMC Infectious Diseases 2009, 9:191 http://www.biomedcentral.com/1471-2334/9/191
Page 4 of 6
(page number not for citation purposes)
prevalence increased with the dates of study publication
due to the technological improvement of the HPV meas-
uring methods. This situation may also be generalized to
our study as well [16].
In 2007, Sanjosé et al. reported that overall HPV preva-
lence in 157.879 women with normal cervical cytology
was estimated to be 10.4% in a meta-analysis of 78 studies
[17]. In 2008, Bao et al. reported that overall HPV preva-
lence was 14.4% in Asia in a meta-analysis of 79 studies
which including 25,368 women [16]. In this study, for
women with normal cytology/histology, HPV prevalence
had a smaller range of 14.0% in southeastern Asia to
14.4% in south central Asia. On the other hand, in an
another meta-analysis including the results of 15.613
women, overall HPV prevalence was 8.7%,14.3% and
5.2% for Asia, South America and Europe, respectively [3].
In our study, the rate of HPV positivity in women with
normal cervical cytology was 20%. Variations between
studies most likely reflect differences in the population
studied with respect to risk factors for exposure to HPV
and methods of evaluations.
In women with abnormal cytology results, the presence of
HPV infection has been reported in 28.8%-61.3% of cases
[18-22]. In our study, HPV was positive in 36% of women
with abnormal cytology. This low rate of HPV in women
with abnormal cytology could be explained by the false
evaluation of the Pap test of women which was referred to
our instution. HPV infection by multiple genotypes has
been reported to occur in 10% to 20% of HPV-positive
cases and to show dependence on HPV type, age of the
patient, and the presence of cytologic abnormalities [23].
Interestingly, we also found that 8.9% of HPV-infected
women has more than one HPV genotype in women with
normal cervical cytology while this percentage was 11.8 in
women with abnormal cervical cytology (p > 0.05). In
other studies, this figures varies between 7% and 23%
depending on the cytological diagnosis. Double infection
with HPV 16 and 18 was found 6.6% in women with nor-
mal cervical cytology. Arora et al. reported the 6.7% of the
women with normal cytology had double infection with
HPV 16 and 18 [24]. Therefore, Arora et al suggested that
the cases who are HPV positive for any of the high risk
types but have concurrently negative Pap smear or no vis-
ible lesions should be followed up more frequently than
the HPV negative cases as they have a substantially greater
risk of developing an abnormal smear [24,25]
Some epidemiologic studies reported that a significant
reduction in HPV prevalence throughout the third decade
of life [26]. It has also been reported that HPV prevalence
is between 32-64% in women under 25 years-old women
while this figure between 2-4% in women older than 45
years old [27]. Similarly, in our study the rate of HPV
infection was 34% in women under 30 years old and this
rate was significantly higher than women older than 30
years old. Hovewer, there was no significant differences in
HPV prevalence by decads of life in patients with normal
cervical cytology (Table 3). This situation also needs to be
explanation. On the other hand, it is weel known, HPV-16
is the most prevalent type worldwide. However, the sec-
ond most prevalent one is HPV-18 in Western countries,
whereas it is HPV-58 in Asia [6]. HPV 16, 6 and 18 were
the most common three type in our study population as
in western countries [23]. On the other hand, HPV preva-
Table 3: HPV prevalence by age in women with normal cervical 
cytology (n = 310)
Age HPV (+)/total no. of patients HPV% P PR*
20-29 17/59 28.8 0.29 1.78
30-39 20/124 16.1
40-49 15/83 18.1 1.12
50-59 7/38 18.4 1.14
>60 2/6 33.3 2.07
* PR: Prevalance ratio for each other age group compared to age 30-
39
Table 4: HPV studies reported from Turkey
NM e t h o d%
Ege SSK Hospital, Ýzmir [4] 1353 HC-II 2.1
Hacettepe University Hospital, Ankara [5] 1032 HC-II 4
Erciyes University Hospital, Kayseri [6] 230 HC-I 6
Total 2615 Mean of HCs 4%
Numune Hospital, Ankara [7] 134 PCR 2.2
Hacettepe University Hospital-2, Ankara [8] 60 PCR 3.3
Baskent University Hospital, Ankara (Current study) 403 PCR 20
Total 597 Mean of PCRs 8.5%
HC: Hybride Capture, PCR:Polymerase chain reactionBMC Infectious Diseases 2009, 9:191 http://www.biomedcentral.com/1471-2334/9/191
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lence was reported to be 81.0% in women with HSIL. The
ten most common HPV types were 16, 58, 52, 18, 33, 51,
31, 56, 35, and 45 in HSIL [16]. Onan et al from Turkey
reported that 45% of the women with cervical intraepithe-
lial neoplasia (CIN) had high risk HPV [28]. Inal et al. per-
formed HC-II study in 1353 women from Izmir region
which has the highest cervical cancer incidence in Turkey,
and reported 2.1% women had positive for HPV. Hov-
ewer, all the women with cytological abnormalities had
positive for HPV DNA. Therefore, the authors concluded
that "In spite of low general frequency of cervical HPV col-
onization, there was a strong correlation between HPV
and CIN" [4]. In our study, HPV was positive in 36% of
the cases with cytological abnormalities.
Conlusion
In conclusion, although geographicly Turkey is located
between Europe and Asia, HPV prevalence and genotypes
are similar to those reported from western countries in
Turkish women with normal and abnormal cytology.
Hovewer, HPV prevalence was more common compared
with previous studies reported from Turkey. This might be
related with methodology and hospital based patient
accrual and high rate of women with abnormal cytology.
Further population based prospective studies are needed
to eliminate the drawbacks of our study and to determine
nonhospital based HPV prevalence in Turkish women.
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